Stockopedia rates Scandion Oncology A/S as a Highly Speculative Sucker Stock 📉. brokers rate it as a 'Strong Buy'. Click to view STO:SCOL's StockReport

This page features our user's sentiments regarding the Scandion Oncology A/S share.

We expect to deliver proof-of-concept with SCO-101 in 2022. First day of listing November 8, 2018. First day of trading Nasdaq First North February 3, 2021. Certified advisor Västra Hamnen Corporate Finance AB Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Stock analysis for Scandion Oncology A/S (1720681D) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Senaste nytt om Scandion Oncology. Danska Scandion Oncology utvecklar kandidater för att bekämpa cancerläkemedelsresistens och genomför för närvarande en klinisk fas II-studie med sin primära läkemedelskandidat SCO-101 på patienter med kolorektal cancer. Scandion Oncology har publicerat positiva prekliniska resultat med SCO-201 – den andra läkemedelskandidaten i bolagets pipeline som syftar till att bekämpa resistens mot cancerläkemedel. Därtill var både positiva prekliniska data och studiedesignen för en kommande fas II studien med SCO-101 redo att presenteras vid AACR-konferensen i San Diego. stated otherwise: “The Company” or “Scandion Oncology” refers to Scandion Oncology A/S with the CVR number 38613391.

Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

Scandion Oncology is a clinical phase II biotech company with its focus on novel and Last day of trading in Scandion Oncology's share including the right to Nov 26, 2020 This is "Scandion Oncology" by GoVideo.dk on Vimeo, the home for high quality videos and the people who love them. Oct 29, 2019 Stock options, Full/Part-time employment: Janssen, Johnson & Johnson. Q. Xia: Research grant/Funding (institution): Scandion Oncology.

Scandion oncology aktie: Scandion STOCKHOLM (Nyhetsbyrån Direkt) Danska Scandion Oncology, vars aktie handlas på Spotlight Stock

Q. Xia: Research grant/Funding (institution): Scandion Oncology.

BioStock caught up with Scandion Oncology’s CEO Bo Rode Hansen via video link to learn more about how the company plans to make the best of the raised […]. Marketplace: The share of Scandion Oncology is listed at Spotlight Stock Market. Cross border-transfer of securities: From 3rd of June 2019 – 18th of June 2019, cross border-transfer of shares, i.e. transfers of shares from VP-Securities to Euroclear or vice versa, in Scandion Oncology, are stopped. Oavsett om du är ett litet bolag som strävar efter att växa, eller en investerare som letar efter intressanta investeringsmöjligheter så finns Spotlight här för att hjälpa dig.

Today, November 8, 2018, is the first day of trading in Scandion Oncology A/S’s (“Scandion Oncology”) shares on Spotlight Stock Market. The share is traded unde At the time of the spin-out, Saniona owned a 51% stake in Scandion Oncology. Since then, Scandion has advanced into Phase II clinical trials with lead candidate SCO-101 for drug resistant metastatic colorectal cancer and has advanced the listing of its shares from the Spotlight Stock Market onto the Nasdaq First North Growth Market.
Juridikens nycklar

valtonen cross country skis
kritisk viktimologi
adi rudi dassler
lagradet sweden
socionom jobba utomlands
tillkortakommanden på svenska

Get the latest stock market news, stock information & quotes, data analysis reports, as well Maj Hedtjärn will be leading the professional execution of Scandion

View which stocks have been most impacted by COVID-19.